Characteristics of Complement Protein Deposition in Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposition.
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
24
05
2023
accepted:
08
09
2023
pubmed:
15
9
2023
medline:
15
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
Hypocomplementemia and complement co-deposition with monoclonal immunoglobulins in glomeruli are not rare in proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID). Deposition of monoclonal immunoglobulins in glomeruli has been suggested to activate complement and cause kidney injury. However, the profiles of complement activation in PGNMID and their clinical and pathologic significance need to be clarified. Forty-six patients with PGNMID were enrolled. Proteomic analysis of glomeruli using laser microdissection and mass spectrometry was performed for ten patients with PGNMID to determine the composition of glomerular deposits. Kidney deposition of complement components was detected by immunohistochemistry and immunofluorescence. Urinary and plasma levels of complement components were measured by an enzyme-linked immunosorbent assay. Group differences were assessed using t tests or Mann-Whitney U tests depending on the distribution. Correlation analysis was performed using Spearman rank correlation or Pearson correlation. Laser microdissection and mass spectrometry-based proteomic analysis showed that complement components were the most enriched proteins deposited in the glomeruli of patients with PGNMID. Glomerular deposition of C3c, C4d, and C5b-9 was detected in most patients. Levels of urinary and plasma C3a, C5a, soluble C5b-9, C4d, Bb, and C1q as well as urinary mannose-binding lectin were significantly higher in patients with PGNMID compared with healthy controls. The intensity of C3c and C4d deposition in glomeruli correlated with serum creatinine and the percentage of crescents, respectively. Furthermore, levels of urinary complement components correlated positively with serum creatinine, urinary protein excretion, percentage of crescents, and global glomerulosclerosis in kidney biopsies, whereas plasma levels of most complement components did not show a significant correlation with clinicopathologic parameters. In multivariable analysis, a higher level of urinary C4d was identified as an independent risk factor of kidney failure. The complement system was found to be overactivated in PGNMID, and levels of urinary complements correlated with disease severity. A higher level of urinary C4d was identified as an independent risk factor of kidney failure.
Sections du résumé
BACKGROUND
BACKGROUND
Hypocomplementemia and complement co-deposition with monoclonal immunoglobulins in glomeruli are not rare in proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID). Deposition of monoclonal immunoglobulins in glomeruli has been suggested to activate complement and cause kidney injury. However, the profiles of complement activation in PGNMID and their clinical and pathologic significance need to be clarified.
METHODS
METHODS
Forty-six patients with PGNMID were enrolled. Proteomic analysis of glomeruli using laser microdissection and mass spectrometry was performed for ten patients with PGNMID to determine the composition of glomerular deposits. Kidney deposition of complement components was detected by immunohistochemistry and immunofluorescence. Urinary and plasma levels of complement components were measured by an enzyme-linked immunosorbent assay. Group differences were assessed using t tests or Mann-Whitney U tests depending on the distribution. Correlation analysis was performed using Spearman rank correlation or Pearson correlation.
RESULTS
RESULTS
Laser microdissection and mass spectrometry-based proteomic analysis showed that complement components were the most enriched proteins deposited in the glomeruli of patients with PGNMID. Glomerular deposition of C3c, C4d, and C5b-9 was detected in most patients. Levels of urinary and plasma C3a, C5a, soluble C5b-9, C4d, Bb, and C1q as well as urinary mannose-binding lectin were significantly higher in patients with PGNMID compared with healthy controls. The intensity of C3c and C4d deposition in glomeruli correlated with serum creatinine and the percentage of crescents, respectively. Furthermore, levels of urinary complement components correlated positively with serum creatinine, urinary protein excretion, percentage of crescents, and global glomerulosclerosis in kidney biopsies, whereas plasma levels of most complement components did not show a significant correlation with clinicopathologic parameters. In multivariable analysis, a higher level of urinary C4d was identified as an independent risk factor of kidney failure.
CONCLUSIONS
CONCLUSIONS
The complement system was found to be overactivated in PGNMID, and levels of urinary complements correlated with disease severity. A higher level of urinary C4d was identified as an independent risk factor of kidney failure.
Identifiants
pubmed: 37713183
doi: 10.2215/CJN.0000000000000295
pii: 01277230-202312000-00010
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1573-1582Subventions
Organisme : National Natural Science Foundation of China
ID : 82070747
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022CR07
Informations de copyright
Copyright © 2023 by the American Society of Nephrology.
Références
Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45–59. doi: 10.1038/s41581-018-0077-4
doi: 10.1038/s41581-018-0077-4
Sethi S, Rajkumar SV, D'Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol. 2018;29(7):1810–1823. doi: 10.1681/ASN.2017121319
doi: 10.1681/ASN.2017121319
Nasr SH, Markowitz GS, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int. 2004;65(1):85–96. doi: 10.1111/j.1523-1755.2004.00365.x
doi: 10.1111/j.1523-1755.2004.00365.x
Bridoux F, Javaugue V, Nasr SH, Leung N. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective. Nephrol Dial Transplant. 2021;36(2):208–215. doi: 10.1093/ndt/gfz176
doi: 10.1093/ndt/gfz176
Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20(9):2055–2064. doi: 10.1681/ASN.2009010110
doi: 10.1681/ASN.2009010110
Bhutani G, Nasr SH, Said SM, et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clinic Proc. 2015;90(5):587–596. doi: 10.1016/j.mayocp.2015.01.024
doi: 10.1016/j.mayocp.2015.01.024
Leung N, Drosou ME, Nasr SH. Dysproteinemias and glomerular disease. Clin J Am Soc Nephrol. 2018;13(1):128–139. doi: 10.2215/CJN.00560117
doi: 10.2215/CJN.00560117
Guiard E, Karras A, Plaisier E, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol. 2011;6(7):1609–1616. doi: 10.2215/CJN.10611110
doi: 10.2215/CJN.10611110
Liu M, Yu X, Wang S, Qin A, Zhou F, Zhao M. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: an entity associated with distinct diseases and comparison between IgG1 and IgG3 subtypes. J Nephrol. 2022;35(9):2363–2372. doi: 10.1007/s40620-022-01317-w
doi: 10.1007/s40620-022-01317-w
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi: 10.3389/fimmu.2014.00520
doi: 10.3389/fimmu.2014.00520
Miller P, Xiao AY, Kung VL, et al. Progression of proliferative glomerulonephritis with monoclonal IgG deposits in pediatric patients. Pediatr Nephrol. 2021;36(4):927–937. doi: 10.1007/s00467-020-04763-5
doi: 10.1007/s00467-020-04763-5
Sethi S, Theis JD, Vrana JA, et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol. 2013;8(6):915–921. doi: 10.2215/CJN.07030712
doi: 10.2215/CJN.07030712
Chen Z, Zhou B, Wang X, et al. Synergistic effects of mechanical stimulation and crimped topography to stimulate natural collagen development for tendon engineering. Acta Biomater. 2022;145:297–315. doi: 10.1016/j.actbio.2022.04.026
doi: 10.1016/j.actbio.2022.04.026
Xing G-q, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol. 2009;29(3):282–291. doi: 10.1007/s10875-008-9268-2
doi: 10.1007/s10875-008-9268-2
Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8(9):1515–1523. doi: 10.2215/CJN.10491012
doi: 10.2215/CJN.10491012
Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17(6):1724–1734. doi: 10.1681/ASN.2005090923
doi: 10.1681/ASN.2005090923
Nauta AJ, Raaschou-Jensen N, Roos A, et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol. 2003;33(10):2853–2863. doi: 10.1002/eji.200323888
doi: 10.1002/eji.200323888
Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell Mol Med. 2008;12(4):1074–1084. doi: 10.1111/j.1582-4934.2008.00350.x
doi: 10.1111/j.1582-4934.2008.00350.x
Takehara E, Mandai S, Shikuma S, et al. Post-infectious proliferative glomerulonephritis with monoclonal immunoglobulin G deposits associated with complement factor H mutation. Intern Med. 2017;56(7):811–817. doi: 10.2169/internalmedicine.56.7778
doi: 10.2169/internalmedicine.56.7778
Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15(3):129–143. doi: 10.1038/s41581-018-0107-2
doi: 10.1038/s41581-018-0107-2
Wilson MR, Arroyave CM, Miles L, Tan EM. Immune reactants in cryoproteins. Relationship to complement activation. Ann Rheum Dis. 1977;36(6):540–548. doi: 10.1136/ard.36.6.540
doi: 10.1136/ard.36.6.540
Haydey RP, de Rojas MP, Gigli I. A newly described control mechanism of complement activation in patients with mixed cryoglobulinemia (cryoglobulins and complement). J Invest Dermatol. 1980;74(5):328–332. doi: 10.1111/1523-1747.ep12543575
doi: 10.1111/1523-1747.ep12543575
Ohsawa I, Ohi H, Tamano M, et al. Cryoprecipitate of patients with cryoglobulinemic glomerulonephritis contains molecules of the lectin complement pathway. Clin Immunol. 2001;101(1):59–66. doi: 10.1006/clim.2001.5098
doi: 10.1006/clim.2001.5098
Sethi S, Palma LMP, Theis JD, Fervenza FC. Proteomic analysis of complement proteins in glomerular diseases. Kidney Int Rep. 2023;8(4):827–836. doi: 10.1016/j.ekir.2023.01.030
doi: 10.1016/j.ekir.2023.01.030
Gupta N, Kaur H, Wajid S. Renal amyloidosis: an update on diagnosis and pathogenesis. Protoplasma. 2020;257(5):1259–1276. doi: 10.1007/s00709-020-01513-0
doi: 10.1007/s00709-020-01513-0
Ikura H, Endo J, Kitakata H, Moriyama H, Sano M, Fukuda K. Molecular mechanism of pathogenesis and treatment strategies for AL amyloidosis. Int J Mol Sci. 2022;23(11):6336. doi: 10.3390/ijms23116336
doi: 10.3390/ijms23116336
Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant. 2003;18(11):2232–2239. doi: 10.1093/ndt/gfg304
doi: 10.1093/ndt/gfg304
Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int. 2012;81(7):628–639. doi: 10.1038/ki.2011.497
doi: 10.1038/ki.2011.497